|
CH415963A
(de)
|
1964-09-04 |
1966-06-30 |
Wander Ag Dr A |
Masse zur Herstellung von Tabletten mit protrahierter Wirkung
|
|
AT264666B
(de)
|
1965-06-10 |
1968-09-10 |
Elektroprojekt Berlin Veb |
Schaltungsanordnung zur automatischen Stillsetzung von Umkehr- und Einwegbandwalzgerüsten
|
|
US3577514A
(en)
|
1968-06-10 |
1971-05-04 |
Pfizer |
Sustained release pharmaceutical tablets
|
|
FR2415099A1
(fr)
|
1978-01-20 |
1979-08-17 |
Ile De France |
Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
|
|
US4590062A
(en)
|
1984-04-16 |
1986-05-20 |
Tech Trade Corp. |
Dry direct compression compositions for controlled release dosage forms
|
|
US4816264A
(en)
|
1986-06-06 |
1989-03-28 |
Warner-Lambert Company |
Sustained release formulations
|
|
IT1200178B
(it)
|
1986-07-23 |
1989-01-05 |
Alfa Farmaceutici Spa |
Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
|
|
JP2572673B2
(ja)
|
1990-07-25 |
1997-01-16 |
エスエス製薬株式会社 |
徐放性錠剤
|
|
US5316772A
(en)
|
1990-12-19 |
1994-05-31 |
Solvay & Cie, S.A. (Societe Anonyme) |
Bilayered oral pharmaceutical composition with pH dependent release
|
|
JP3157158B2
(ja)
|
1990-12-20 |
2001-04-16 |
ウオーナージェンキンソン カンパニー インコーポレイテッド |
湿式粉末膜形成組成物
|
|
US5591455A
(en)
|
1990-12-20 |
1997-01-07 |
Warner-Jenkinson Company, Inc. |
Wet powder film-forming compositions
|
|
GB2256648B
(en)
|
1991-05-29 |
1995-08-30 |
Colorcon Ltd |
Wax polish composition
|
|
EP0520119A1
(fr)
|
1991-06-17 |
1992-12-30 |
Spirig Ag Pharmazeutische Präparate |
Composition à base de diclofenac pour l'administration orale
|
|
TW245641B
(fr)
|
1993-04-26 |
1995-04-21 |
Takeda Pharm Industry Co |
|
|
WO1997044025A1
(fr)
|
1996-05-23 |
1997-11-27 |
G.D. Searle & Co. |
Compositions pharmaceutiques contenant du verapamil non racemique et procede pour optimiser l'activite pharmaceutique du r- et s-verapamil
|
|
IT1283124B1
(it)
|
1996-06-12 |
1998-04-07 |
Prodotti Antibiotici Spa |
Forme e composizioni farmaceutiche per il trattamento dell'ipertrofia prostatica benigna
|
|
FR2753376B1
(fr)
|
1996-09-18 |
1998-10-16 |
Synthelabo |
Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques
|
|
CN1230883A
(zh)
|
1996-09-24 |
1999-10-06 |
伊莱利利公司 |
包衣颗粒制剂
|
|
US5837379A
(en)
|
1997-01-31 |
1998-11-17 |
Andrx Pharmaceuticals, Inc. |
Once daily pharmaceutical tablet having a unitary core
|
|
US5922352A
(en)
|
1997-01-31 |
1999-07-13 |
Andrx Pharmaceuticals, Inc. |
Once daily calcium channel blocker tablet having a delayed release core
|
|
FR2762213B1
(fr)
|
1997-04-18 |
1999-05-14 |
Synthelabo |
Composition pharmaceutique a retention gastrique
|
|
US6210710B1
(en)
|
1997-04-28 |
2001-04-03 |
Hercules Incorporated |
Sustained release polymer blend for pharmaceutical applications
|
|
US20050281752A1
(en)
|
1997-10-01 |
2005-12-22 |
Dugger Harry A Iii |
Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
|
|
PT1035834E
(pt)
|
1997-12-05 |
2002-09-30 |
Alza Corp |
Forma de dosagem osmotica que compreende primeiro e segundo revestimentos
|
|
US6169094B1
(en)
*
|
1998-07-14 |
2001-01-02 |
Sanofi-Synthelabo |
Compositions of (S) (-)-amisulpride
|
|
CO5140079A1
(es)
|
1998-10-14 |
2002-03-22 |
Novartis Ag |
Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
|
|
FR2784583B1
(fr)
|
1998-10-16 |
2002-01-25 |
Synthelabo |
Composition pharmaceutique a residence gastrique et a liberation controlee
|
|
JP2002531431A
(ja)
|
1998-12-02 |
2002-09-24 |
ダーウィン・ディスカバリー・リミテッド |
治療用製品およびその使用
|
|
US6897242B1
(en)
|
1999-02-24 |
2005-05-24 |
Judson J. Somerville |
Non-racemic mixtures of d- and l- methadone and method of treating pain
|
|
CA2431041A1
(fr)
|
2001-01-02 |
2002-07-11 |
Pharmacia & Upjohn Company |
Nouvelles combinaisons medicamenteuses d'inhibiteurs de recaptage de la norepinehrine et d'agents neuroleptiques
|
|
US20030096264A1
(en)
|
2001-06-18 |
2003-05-22 |
Psychiatric Genomics, Inc. |
Multi-parameter high throughput screening assays (MPHTS)
|
|
DE10129320A1
(de)
|
2001-06-19 |
2003-04-10 |
Norbert Mueller |
Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
|
|
US20110130390A1
(en)
|
2001-06-19 |
2011-06-02 |
Mueller Norbert |
Use of COX-2 Inhibitors for the Treatment of Schizophrenia, Delusional Disorders, Affective Disorders, Autism or Tic Disorders
|
|
JP4205577B2
(ja)
|
2001-06-19 |
2009-01-07 |
ミュラー，ノルベルト |
精神分裂病、妄想障害、情動障害、自閉症またはチック障害の治療のためのｃｏｘ−２阻害薬の使用
|
|
US20060167074A1
(en)
|
2001-06-19 |
2006-07-27 |
Norbert Muller |
Methods and compositions for the treatment of psychiatric disorders
|
|
US7544681B2
(en)
|
2001-09-27 |
2009-06-09 |
Ramot At Tel Aviv University Ltd. |
Conjugated psychotropic drugs and uses thereof
|
|
DE10153078A1
(de)
|
2001-10-30 |
2003-05-22 |
Degussa |
Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
|
|
US7815936B2
(en)
|
2001-10-30 |
2010-10-19 |
Evonik Degussa Gmbh |
Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
|
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
US20050085463A1
(en)
|
2003-01-23 |
2005-04-21 |
Weiner David M. |
Use of N-desmethylclozapine to treat human neuropsychiatric disease
|
|
US20050250767A1
(en)
|
2003-01-23 |
2005-11-10 |
Weiner David M |
Use of N-desmethylclozapine to treat human neuropsychiatric disease
|
|
EP1626703A2
(fr)
|
2003-05-22 |
2006-02-22 |
Yeda Research And Development Co. Ltd. |
Dopamine et ses agonistes et antagonistes pour moduler l'activite suppressive de lymphocytes t regulateurs de cd4+cd25+
|
|
FR2857263B1
(fr)
|
2003-07-09 |
2005-09-09 |
Sanofi Synthelabo |
Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
|
|
US20050113314A1
(en)
|
2003-08-29 |
2005-05-26 |
Fong Benson M. |
Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
|
|
US20050181049A1
(en)
|
2003-11-19 |
2005-08-18 |
Dong Liang C. |
Composition and method for enhancing bioavailability
|
|
EP1547650A1
(fr)
|
2003-12-02 |
2005-06-29 |
B & B Beheer NV |
Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des récepteurs D4 et 5-HT2A
|
|
PL1708790T3
(pl)
|
2003-12-02 |
2010-10-29 |
Pharmaneuroboost N V |
Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
|
|
WO2005082370A1
(fr)
|
2004-01-29 |
2005-09-09 |
Pfizer Products Inc. |
Combinaisons d'un antipsychotique atypique et de derives azabicycliques d'aminomethylpyridyloxy- methyle/benzisoxazole pour le traitement de troubles du systeme nerveux central
|
|
BRPI0508254A
(pt)
|
2004-03-02 |
2007-07-24 |
Pharmacia Corp |
métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
|
|
US20060150989A1
(en)
|
2005-01-12 |
2006-07-13 |
Peter Migaly |
Method of diagnosing, treating and educating individuals with and/or about depression
|
|
US20060167068A1
(en)
|
2005-01-26 |
2006-07-27 |
Seth Feuerstein |
Method of treating self-injurious behavior with glutamate modulating agents
|
|
EP1841417A2
(fr)
|
2005-01-28 |
2007-10-10 |
Schwarz Pharma Ag |
Spm 927 pour la thérapie adjuvante de la schizophrenie
|
|
US20110015246A2
(en)
|
2005-03-14 |
2011-01-20 |
Agean Llc |
Lofexidine enantiomers for use as a treatment for cns disease and pathologies and its chiral synthesis
|
|
CA2603939C
(fr)
|
2005-04-08 |
2013-08-27 |
Pfizer Products Inc. |
Heteroarylamides bicycliques [3.1.0 ] comme inhibiteurs de transport de la glycine
|
|
ES2437581T3
(es)
|
2005-11-17 |
2014-01-13 |
Zogenix, Inc. |
Suministro de formulaciones viscosas por inyección sin aguja
|
|
US20110136742A1
(en)
|
2006-02-24 |
2011-06-09 |
Travis Mickle |
Antidepressant prodrugs
|
|
RS20080439A
(en)
|
2006-03-27 |
2009-05-06 |
Panacea Biotec Ltd., |
Sustained release pharmaceutical composition on the basis of a release system comprising an acid-soluble polymer and a ph-dependent polymer
|
|
US8377994B2
(en)
|
2006-05-10 |
2013-02-19 |
Evonik Degussa GmeH |
Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
|
|
US20070264330A1
(en)
|
2006-05-15 |
2007-11-15 |
Bo Ragnar-Tolf |
Pharmaceutical formulations of pimavanserin
|
|
WO2007137224A2
(fr)
|
2006-05-22 |
2007-11-29 |
Vanda Pharmaceuticals, Inc. |
Méthode de traitement
|
|
GB0618879D0
(en)
*
|
2006-09-26 |
2006-11-01 |
Zysis Ltd |
Pharmaceutical compositions
|
|
WO2008070296A2
(fr)
|
2006-10-17 |
2008-06-12 |
The Research Foundation For Mental Hygiene, Inc. |
Système et procédé de diagnostic et de traitement de troubles neuropsychiatriques
|
|
US8394790B2
(en)
|
2006-10-25 |
2013-03-12 |
Ramot At Tel-Aviv University Ltd. |
Psychotropic agents having glutamate NMDA activity
|
|
WO2008065500A2
(fr)
|
2006-11-30 |
2008-06-05 |
Pfizer Products Inc. |
Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i
|
|
EP1946777A1
(fr)
|
2007-01-16 |
2008-07-23 |
Laboratorios del Dr. Esteve S.A. |
Composés de pyrazoline substituée pour éviter la prise de poids
|
|
EP1944295A1
(fr)
|
2007-01-15 |
2008-07-16 |
Laboratorios del Dr. Esteve S.A. |
Mélanges non racémiques de (R)-N-pipéridinyl-5-(4-chlorophényl)1-1(2,4-dichlorophényl)-4,5-dihydro-1H-pyrazole-3-carboxamide et (S)-N-pipéridinyl-5-(4-chlorophényl)-1-(2,4-dichlorophényl)-4,5-dihydro-1H-pyrazole-3-carboxamide
|
|
EP2114150A4
(fr)
|
2007-02-01 |
2010-03-10 |
Alan I Green |
Combinaisons de blocage des récepteurs dopaminergiques d2 avec inhibition de la recaptation de la norépinéphrine et blocage des récepteurs de norépinéphrine alpha 2
|
|
US7825156B2
(en)
*
|
2007-02-02 |
2010-11-02 |
Copharms |
Method of treating bipolar depression with a benzamide derivative
|
|
WO2008116024A2
(fr)
|
2007-03-19 |
2008-09-25 |
Acadia Pharmaceuticals Inc. |
Combinaisons d'agonistes ou antagonistes inverses de 5-ht2a avec antipsychotiques
|
|
GB0707127D0
(en)
|
2007-04-13 |
2007-05-23 |
Zysis Ltd |
Pharmaceutical compositions
|
|
US20080280886A1
(en)
|
2007-05-08 |
2008-11-13 |
Auspex Pharmaceuticals, Inc. |
Substituted ureas
|
|
EP2030619A1
(fr)
|
2007-06-18 |
2009-03-04 |
A.Carlsson Research AB |
Utilisation de stabilisateurs de dopamine
|
|
WO2008155357A2
(fr)
|
2007-06-18 |
2008-12-24 |
A. Carlsson Research Ab |
Utilisation de stabilisateurs de la dopamine
|
|
WO2009017453A1
(fr)
|
2007-07-30 |
2009-02-05 |
Astrazeneca Ab |
Nouvelle combinaison thérapeutique d'antipsychotique et d'inhibiteur de gsk3 958
|
|
EP2198049A1
(fr)
|
2007-09-10 |
2010-06-23 |
Vanda Pharmaceuticals Inc. |
Traitement antipsychotique fondé sur le génotype snp
|
|
US8318813B2
(en)
|
2007-09-13 |
2012-11-27 |
Lcs Group, Llc |
Method of treating binge eating disorder
|
|
US20090082342A1
(en)
|
2007-09-21 |
2009-03-26 |
Acadia Pharmaceuticals, Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
|
JPWO2009057199A1
(ja)
|
2007-10-31 |
2011-03-10 |
財団法人乙卯研究所 |
レチノイドプロドラッグ化合物
|
|
GB2456183A
(en)
|
2008-01-04 |
2009-07-08 |
Gw Pharma Ltd |
Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
|
|
RU2010136023A
(ru)
|
2008-02-01 |
2012-03-10 |
Асцендис Фарма Ас (Dk) |
Пролекарство, содержащее саморасщепляемый линкер
|
|
US20090208979A1
(en)
|
2008-02-14 |
2009-08-20 |
Technion Research And Development Foundation Ltd. |
Method for identifying antipsychotic drug candidates
|
|
WO2009126931A2
(fr)
|
2008-04-11 |
2009-10-15 |
Xvasive, Inc. |
Thérapie combinatoire pour trouble bipolaire
|
|
US20090269770A1
(en)
|
2008-04-24 |
2009-10-29 |
Technion Research And Development Foundation Ltd. |
Methods for evaluation prognosis and follow-up of drug treatment of psychiatric diseases or disorders
|
|
US9267151B2
(en)
|
2008-08-20 |
2016-02-23 |
Brainco Biopharma, S.L. |
STXBP1 overexpressing mouse and its uses in screening of treatments for neuropsychiatric illness
|
|
US20100074973A1
(en)
|
2008-08-27 |
2010-03-25 |
Auspex Pharmaceuticals, Inc. |
Thioxanthene modulators of dopamine d2 receptors
|
|
WO2010023690A2
(fr)
*
|
2008-08-28 |
2010-03-04 |
Torrent Pharmaceuticals Ltd. |
Formulation à libération prolongée d'amisulpride
|
|
US20100119622A1
(en)
|
2008-09-15 |
2010-05-13 |
Auspex Pharmaceuticals, Inc. |
3h-benzooxazol-2-one modulators of d2 receptor and/or 5-ht1a receptor
|
|
US20100069399A1
(en)
|
2008-09-15 |
2010-03-18 |
Auspex Pharmaceutical, Inc. |
Arylpiperazine modulators of d2 receptors, 5-ht1a receptors, and/or 5-ht2a receptors
|
|
US20100069356A1
(en)
|
2008-09-17 |
2010-03-18 |
Auspex Pharmaceuticals, Inc. |
Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
|
|
US20100119624A1
(en)
|
2008-09-17 |
2010-05-13 |
Auspex Pharmaceuticals, Inc. |
Benzisoxazole modulators of d2 receptor and/or 5-ht2a receptor
|
|
US20100266711A1
(en)
|
2008-09-29 |
2010-10-21 |
Auspex Pharmaceuticals, Inc. |
Thienobenzodiazepine modulators of d1 receptor, d2 receptor, and/or 5-ht2 receptor
|
|
US20100159033A1
(en)
|
2008-09-29 |
2010-06-24 |
Auspex Pharmaceuticals, Inc. |
Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor
|
|
MX2011004994A
(es)
|
2008-11-14 |
2011-09-28 |
Y Sk Chemicals Co Ltd Ewha University Industry Collaboration Foundation |
Metodo para preparar microesferas y microesferas producidas por el mismo.
|
|
WO2010058314A1
(fr)
|
2008-11-18 |
2010-05-27 |
Pfizer Inc. |
Hydroxyquinolin-2(1h)-ones et leurs dérivés
|
|
CA2646779A1
(fr)
|
2008-11-25 |
2010-05-25 |
Gerard Voon |
Bioscience ix
|
|
US20100143507A1
(en)
|
2008-12-09 |
2010-06-10 |
Auspex Pharmaceuticals, Inc. |
Carboxylic acid inhibitors of histone deacetylase, gaba transaminase and sodium channel
|
|
WO2010075275A1
(fr)
|
2008-12-23 |
2010-07-01 |
Usworldmeds Llc |
Libération sélective de mélanges non racémiques de deux énantiomères à partir de comprimés et de capsules
|
|
EP3006023B1
(fr)
|
2009-01-20 |
2019-06-26 |
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center |
Acide sorbique et dérivés de celui-ci pour améliorer l'action d'un produit neuropharmaceutique
|
|
KR101597672B1
(ko)
|
2009-03-20 |
2016-02-25 |
앤태어스 파머, 인코퍼레이티드 |
위험 약제 주사 장치
|
|
CN101898991B
(zh)
|
2009-05-31 |
2013-09-25 |
江苏天士力帝益药业有限公司 |
一种(s)(-)-氨磺必利d-(-)-酒石酸盐的合成方法
|
|
US9173953B2
(en)
|
2009-07-31 |
2015-11-03 |
Ascendis Pharma As |
Prodrugs containing an aromatic amine connected by an amido bond to a linker
|
|
GEP20115310B
(en)
|
2009-10-09 |
2011-10-25 |
|
Medicinal preparation of amisulpride in the solid form and the method of its manufacture
|
|
US20110262442A1
(en)
|
2009-11-06 |
2011-10-27 |
Adenios, Inc. |
Compositions for treating cns disorders
|
|
US20110117214A1
(en)
|
2009-11-16 |
2011-05-19 |
Auspex Pharmaceuticals, Inc. |
Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
|
|
AR079814A1
(es)
|
2009-12-31 |
2012-02-22 |
Otsuka Pharma Co Ltd |
Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
|
|
GB201003731D0
(en)
|
2010-03-05 |
2010-04-21 |
Univ Strathclyde |
Immediate/delayed drug delivery
|
|
GB201003734D0
(en)
|
2010-03-05 |
2010-04-21 |
Univ Strathclyde |
Delayed prolonged drug delivery
|
|
GB201003766D0
(en)
|
2010-03-05 |
2010-04-21 |
Univ Strathclyde |
Pulsatile drug release
|
|
GB201004020D0
(en)
|
2010-03-11 |
2010-04-21 |
Acacia Pharma Ltd |
New therapeutic use
|
|
WO2011143534A1
(fr)
|
2010-05-13 |
2011-11-17 |
The Mclean Hospital Corporation |
Méthodes de traitement des troubles psychiatriques
|
|
US20130096319A1
(en)
|
2010-06-17 |
2013-04-18 |
Lupin Limited |
Process for preparation of amisulpride
|
|
WO2012002583A1
(fr)
|
2010-07-02 |
2012-01-05 |
Vanderbilt University |
Procédé de traitement de la schizophrénie et de maladies apparentées au moyen d'une polythérapie
|
|
CN101987081B
(zh)
|
2010-07-16 |
2012-08-08 |
钟术光 |
一种控释制剂
|
|
DE102010033527A1
(de)
|
2010-08-05 |
2012-02-09 |
Acino Pharma Ag |
Quetiapin-Tabletten
|
|
JP2013540748A
(ja)
|
2010-09-16 |
2013-11-07 |
コーネル ユニバーシティー |
血液脳関門の透過性を調節するためのアデノシン受容体シグナル伝達の使用法
|
|
WO2012065110A2
(fr)
|
2010-11-12 |
2012-05-18 |
Promentis Pharmaceuticals, Inc. |
Analogues de cystéine s-protégés et composés associés
|
|
EP2638005A4
(fr)
|
2010-11-12 |
2015-04-01 |
Promentis Pharm Inc |
Analogues dipeptidiques de cystéine protégée par s-t-butyle et composés associés
|
|
WO2012088441A1
(fr)
|
2010-12-23 |
2012-06-28 |
Alkermes, Inc. |
Promédicaments chargés de multiples principes actifs
|
|
WO2012118562A1
(fr)
|
2011-03-02 |
2012-09-07 |
Rhine Pharmaceuticals, Llc |
Compositions et méthodes de traitement de la dépression, du trouble de l'hyperactivité avec déficit de l'attention et d'autres troubles du système nerveux central au moyen de nouveaux composés de bupropione, et procédés de production et d'utilisation de nouveaux composés de bupropione et de formulations associées
|
|
EP2508174A1
(fr)
|
2011-04-06 |
2012-10-10 |
Ljiljana Sovic Brkicic |
Composition pharmaceutique
|
|
CA2836066A1
(fr)
|
2011-05-13 |
2012-11-22 |
Dainippon Sumitomo Pharma Co., Ltd. |
Traitement et controle de troubles du snc
|
|
AR086798A1
(es)
|
2011-06-29 |
2014-01-22 |
Otsuka Pharma Co Ltd |
Derivados quinazolinicos utiles para tratar trastornos del sistema nervioso central y composiciones farmaceuticas que los contienen
|
|
CA2842106A1
(fr)
|
2011-07-28 |
2013-01-31 |
Promentis Pharmaceuticals, Inc. |
Pro-medicaments cysteines
|
|
EP2755651A1
(fr)
*
|
2011-09-13 |
2014-07-23 |
Biomed Valley Discoveries, Inc. |
Compositions et méthodes pour le traitement des troubles métaboliques
|
|
WO2013122554A1
(fr)
|
2012-02-14 |
2013-08-22 |
Mahmut Bilgic |
Formulations de pastilles comprenant de l'ésoméprazole
|
|
CN102600132B
(zh)
|
2012-03-13 |
2014-05-14 |
齐鲁制药有限公司 |
一种含氨磺必利的口服制剂
|
|
JOP20210047A1
(ar)
|
2012-10-25 |
2017-06-16 |
Otsuka Pharma Co Ltd |
عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
|
|
EP2986278A1
(fr)
*
|
2013-03-11 |
2016-02-24 |
DURECT Corporation |
Composition injectable à libération contrôlée comprenant un véhicule liquide à haute viscosité
|
|
WO2014152965A2
(fr)
|
2013-03-14 |
2014-09-25 |
The Children's Hospital Of Philadelphia |
Loci génétiques associés à la schizophrénie identifiés dans des études d'association sur génome total et leur utilisation en tant que nouvelles cibles thérapeutiques
|
|
US20170027958A1
(en)
|
2013-04-02 |
2017-02-02 |
Themis Medicare Limited |
Fulvestrant compositions
|
|
UA119324C2
(uk)
|
2013-04-02 |
2019-06-10 |
Теміс Медікер Лімітед |
Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
|
|
US10098893B2
(en)
|
2013-10-03 |
2018-10-16 |
Northwestern University |
Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
|
|
WO2015085004A1
(fr)
|
2013-12-03 |
2015-06-11 |
Intra-Cellular Therapies, Inc. |
Nouveaux procédés
|
|
CN106715695B
(zh)
|
2014-02-05 |
2020-07-31 |
耶达研究及发展有限公司 |
用于治疗和诊断的微rna和包含所述微rna的组合物
|
|
TW201613864A
(en)
|
2014-02-20 |
2016-04-16 |
Takeda Pharmaceutical |
Novel compounds
|
|
CN106456638A
(zh)
|
2014-04-04 |
2017-02-22 |
细胞内治疗公司 |
有机化合物
|
|
PL3125893T3
(pl)
|
2014-04-04 |
2024-02-12 |
Intra-Cellular Therapies, Inc. |
Deuterowane gamma-karboliny w fuzji z heterocyklami jako antagoniści receptorów 5-HT2A
|
|
EP2959895A1
(fr)
|
2014-06-27 |
2015-12-30 |
Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) |
Compositions comprenant de la phénylalanine et de la leucine pour une utilisation dans le diagnostic et le traitement de troubles neurologiques et leurs symptomes
|
|
ES2562684B1
(es)
|
2014-08-04 |
2017-02-06 |
Consejo Superior De Investigaciones Científicas (Csic) |
Método de monitorización de tratamiento antipsicótico
|
|
US11174514B2
(en)
|
2014-08-29 |
2021-11-16 |
Northwestern University |
Methods, kits, and devices utilizing HTR2C polymorphisms for diagnosing, prognosing, and treating psychiatric disorders in a patient
|
|
WO2016109359A1
(fr)
|
2014-12-29 |
2016-07-07 |
Auspex Pharmaceuticals, Inc. |
Modulateurs de récepteurs de la mélatonine à base de cyclopropyl dihydrobenzofurane
|
|
US20160193151A1
(en)
|
2015-01-06 |
2016-07-07 |
Maria Del Pilar Noriega Escobar |
Dosage form incorporating an amorphous drug solid solution
|
|
CN104725292B
(zh)
|
2015-03-23 |
2017-07-25 |
湖北荆江源制药股份有限公司 |
一种(s)(‑)‑氨磺必利的制备方法
|
|
GB201506116D0
(en)
|
2015-04-10 |
2015-05-27 |
Acacia Pharma Ltd |
Kit and combination therapy for nausea and vomiting
|
|
ITUB20150635A1
(it)
|
2015-04-14 |
2016-10-14 |
Giuseppe Lotito |
Uso di un inibitore dell’aceticolinesterasi e composizioni farmaceutiche contenenti detto inibitore.
|
|
US11426366B2
(en)
|
2015-05-15 |
2022-08-30 |
Arizona Board Of Regents On Behalf Of The Universsity Of Arizona |
Compositions and methods for treating motor disorders
|
|
JP2018527392A
(ja)
|
2015-09-18 |
2018-09-20 |
グリューネンタール・ゲーエムベーハー |
結晶化法及びバイオアベイラビリティ
|
|
CN106890129A
(zh)
*
|
2015-12-18 |
2017-06-27 |
健乔信元医药生技股份有限公司 |
环苄普林之延释剂型
|
|
WO2017149392A1
(fr)
|
2016-03-04 |
2017-09-08 |
Sharon Anavi-Goffer |
Compositions auto-émulsifiantes de modulateurs du récepteur cb2
|
|
WO2018015915A1
(fr)
|
2016-07-22 |
2018-01-25 |
Cadila Healthcare Limited |
Composition à libération parentérale contrôlée d'un antipsychotique atypique.
|
|
US10336679B2
(en)
|
2016-10-24 |
2019-07-02 |
Syneurx International (Taiwan) Corp. |
Polymorphic forms of sodium benzoate and uses thereof
|
|
US20180118967A1
(en)
*
|
2016-10-31 |
2018-05-03 |
Xerox Corporation |
Metal Nanoparticle Ink Compositions For Printed Electronic Device Applications
|
|
US11377421B2
(en)
|
2016-11-28 |
2022-07-05 |
Lb Pharmaceuticals Inc. |
Psychotropic agents and uses thereof
|
|
CN106995397B
(zh)
*
|
2016-12-12 |
2020-01-14 |
河北医科大学 |
R-氨磺必利药用盐、制备方法、晶型及其用途
|
|
CN107126422B
(zh)
|
2017-03-02 |
2020-07-07 |
河北龙海药业有限公司 |
一种氨磺必利片剂及其制备方法
|
|
CN107049981A
(zh)
|
2017-04-11 |
2017-08-18 |
深圳市泛谷药业股份有限公司 |
一种速释氨磺必利药物组合物及其制备方法
|
|
EP3615053A4
(fr)
|
2017-04-25 |
2021-07-14 |
Temple Otorongo LLC |
Composition pharmaceutique comprenant du tryptophane et un dérivé de phyllokinine destinée à être utilisée dans le traitement de troubles psychiatriques et psychologiques
|
|
US10441544B2
(en)
|
2017-10-10 |
2019-10-15 |
Douglas Pharmaceuticals, Ltd. |
Extended release pharmaceutical formulation
|
|
JP2021505595A
(ja)
|
2017-12-05 |
2021-02-18 |
サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． |
結晶形およびその製造方法
|
|
SG11202005016SA
(en)
|
2017-12-05 |
2020-06-29 |
Sunovion Pharmaceuticals Inc |
Nonracemic mixtures and uses thereof
|
|
CN109010300A
(zh)
|
2018-10-24 |
2018-12-18 |
湖南洞庭药业股份有限公司 |
一种氨磺必利片及其制备方法
|
|
CN114401717A
(zh)
|
2019-06-04 |
2022-04-26 |
赛诺维信制药公司 |
修饰释放配制品及其用途
|
|
WO2020247603A1
(fr)
|
2019-06-04 |
2020-12-10 |
Sunovion Pharmaceuticals Inc. |
Formulations à libération modifiée et utilisations associées
|